Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma

Publisher DOI
PubMed ID
21377838
Abstract
There is currently no curative therapy for cutaneous T cell lymphoma (CTCL). New therapies are therefore needed. Telomerase, the enzyme that allows for unrestricted cell divisions of cancer cells, is a promising target for cancer therapy. The telomerase-specific peptide vaccination GV1001 has shown promising results in previous studies. Since telomerase is expressed in malignant cells of CTCL, GV1001 vaccination in CTCL is a promising new therapeutic approach.
Date Issued
2011
Publication Type
Article
Language(s)
en
Author(s)
Daubner, Barbara
Additional Credits
Journal
Journal of dermatological science
Publisher
Elsevier
ISSN
0923-1811
Access(Rights)
metadata.only
Show full item